2025-521919-39-00招募中1 期
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting
H e x a l AG4 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2026年1月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 8
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Biosimilar Clinical Trials Information Point
Scientific
H e x a l AG
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A study to investigate JNJ-80202135 (nipocalimab) delivered subcutaneously via prefilled syringe autoinjector and via normal syringeHealthy Volunteers2023-504280-16-00Janssen - Cilag International60
已完成
1 期
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)Metastatic cancerEpithelial tumours2023-503525-19-00Akamis Bio Limited85
招募中
1 期
A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple MyelomaMultiple Myeloma2024-515316-44-00Janssen Cilag International32
招募中
3 期
Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal
cancerMicrosatellite Instability High (MSI-H) or Mismatch Repair Deficient
Metastatic Colorectal Cancer (dMMR)2023-503956-29-00Bristol Myers Squibb International Corporation571
招募中
3 期
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT07258511Janssen Research & Development, LLC400